ArticleBMC gastroenterology2025
TPD52 promotes the proliferation and metastasis of gastric cancer cells.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Immunotherapy has improved outcomes for tumor patients, but only a small proportion benefits due to genetic and immunological resistance. Enhancing its efficacy is crucial. Tumor protein D52 (TPD52), a novel immune checkpoint expressed in T cells, B cells, and NK cells, plays a key role in immune regulation. This research aimed to investigate the prognostic value of TPD52 in gastric cancer (GC) and explore its biological functions. We analyzed the TCGA and GEO dataset to assess the transcriptional expression, prognostic significance, immune infiltration, and related biological functions of TPD52. Biological functions of TPD52 in GC cells were studied using CCK-8, colony formation, and transwell assays, while quantitative real-time PCR was used to assess TPD52 expression in the serum of GC patients. ROC analysis evaluated its diagnostic efficiency for GC. Results showed that TPD52 was dysregulated in most tumors and adjacent normal tissues, significantly impacting prognosis. TPD52 expression was strongly correlated with immune cell infiltration, tumor molecular subtypes, and immune checkpoint-regulated genes. Elevated TPD52 expression in GC cell lines promoted cell proliferation, migration, and invasion. Additionally, TPD52 levels were higher in the serum of GC patients, and their combination with CEA and CA199 enhanced its diagnostic efficiency for GC. In conclusion, TPD52 influences immune responses, immune cell infiltration, and tumor malignancy, making it a promising therapeutic target and biomarker for GC prognosis and immune infiltration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.